ACTEMRA offers a range of treatment method options for your RA symptoms. These options give you the ability to take your medicine in a way that may be convenient for you. ACTEMRA is available to treat rheumatoid arthritis (RA) as:
Know the facts about ACTEMRA SC injections before deciding if they’re right for you:
You’ll be trained by your healthcare provider or nurse
Medicine is injected under the skin into fatty tissue (for example in the belly or upper thigh) but not deeper into the muscle
Your healthcare provider will tell you if you should give yourself an ACTEMRA SC injection once a week or once every two weeks. This is based on weight, but it may be adjusted depending on your response to treatment
Before you decide if ACTEMRA IV infusions are the option for you, learn more about them:
IV infusions are given to you at your healthcare provider's office or in an infusion center
Liquid medicine is given by needle directly into your vein
You’ll sit in a comfortable chair or lie down on a cot or bed
Your IV infusion will last about 1 hour
Infusion reactions may occur. A healthcare provider or nurse will be there to monitor you
Your healthcare provider may increase or decrease your dose depending on your response to treatment
If you have or are a carrier of the hepatitis B virus (a virus that affects the liver), the virus may become active while you use ACTEMRA. Your healthcare provider may do blood tests before you start treatment with ACTEMRA and while you are using ACTEMRA. Tell your healthcare provider if you have any signs of these symptoms:
ACTEMRA is FDA approved for the treatment of adults hospitalized with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Ask your doctor when ACTEMRA may be an appropriate treatment for you.
For Important Safety Information please see the full Prescribing Information and Medication Guide, including SERIOUS SIDE EFFECTS.
The US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for use of ACTEMRA to treat coronavirus disease 2019 (COVID-19) in pediatric patients (two years of age and older) who are in the hospital and who are receiving corticosteroids and require supplemental oxygen, or a machine that helps with their breathing (ventilator) or a machine that adds oxygen to the blood outside the body (extracorporeal membrane oxygenation or ECMO). ACTEMRA is not FDA-approved for use in pediatric patients with COVID-19.
Download the EUA Patient Fact Sheet here to understand the potential risks and benefits of taking ACTEMRA.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.